Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kiniksa Pharmaceuticals International Plc (KNSA)

Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,736,611
  • Shares Outstanding, K 70,940
  • Annual Sales, $ 270,260 K
  • Annual Income, $ 14,080 K
  • 60-Month Beta 0.33
  • Price/Sales 6.40
  • Price/Cash Flow N/A
  • Price/Book 3.98
Trade KNSA with:

Options Overview Details

View History
  • Implied Volatility 64.49% ( +8.22%)
  • Historical Volatility 33.14%
  • IV Percentile 63%
  • IV Rank 61.83%
  • IV High 101.49% on 06/27/24
  • IV Low 4.56% on 06/12/24
  • Put/Call Vol Ratio 4.00
  • Today's Volume 10
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 2,532
  • Open Int (30-Day) 2,505

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.06
  • Low Estimate -0.06
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +95.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.16 +2.48%
on 09/09/24
26.78 -11.39%
on 09/19/24
-1.20 (-4.81%)
since 09/06/24
3-Month
19.38 +22.45%
on 07/08/24
27.92 -15.01%
on 08/26/24
+4.37 (+22.57%)
since 07/05/24
52-Week
14.12 +68.06%
on 11/10/23
27.92 -15.01%
on 08/26/24
+7.27 (+44.17%)
since 10/06/23

Most Recent Stories

More News
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

KNSA : 23.73 (-3.06%)
LGND : 102.62 (-2.06%)
SCI : 75.00 (-1.54%)
VBR : 198.08 (-0.73%)
VKTX : 63.01 (-3.00%)
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,695.94 (-0.96%)
NVO : 117.77 (+2.30%)
BIIB : 183.34 (-1.26%)
KNSA : 23.73 (-3.06%)
SWTX : 32.27 (-1.13%)
RLAY : 6.34 (-2.91%)
ADPT : 5.41 (-1.99%)
GS : 494.62 (-0.11%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 53.85 (-9.01%)
KNSA : 23.73 (-3.06%)
ACAD : 14.73 (-2.45%)
HRMY : 34.38 (-0.64%)
AMPH : 46.83 (+0.24%)
INCY : 65.76 (-2.56%)
AGEN : 4.65 (-4.52%)
NVS : 113.86 (-0.08%)
PFE : 29.20 (+2.17%)
SGEN : 228.74 (-0.07%)
MRK : 108.59 (-1.07%)
RXDX : 199.92 (+0.09%)
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday

The company reported a big jump in revenue and updated guidance.

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference

HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in...

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront...

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as...

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash...

KNSA : 23.73 (-3.06%)
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022

HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...

KNSA : 23.73 (-3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 25.51
2nd Resistance Point 25.00
1st Resistance Point 24.36
Last Price 23.73
1st Support Level 23.21
2nd Support Level 22.70
3rd Support Level 22.06

See More

52-Week High 27.92
Last Price 23.73
Fibonacci 61.8% 22.65
Fibonacci 50% 21.02
Fibonacci 38.2% 19.39
52-Week Low 14.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar